Categories

EMA Confirms Rejection of Neurodegenerative Disease Drugs

EMA Confirms Rejection of Neurodegenerative Disease Drugs

Views: 301

The European Medicines Agency (EMA) has upheld an earlier recommendation to deny marketing authorization for Masitinib AB Science (masitinib), an oral treatment for amyotrophic lateral sclerosis (ALS).  In a meeting on October 17, the EMA’s Committee for Medicinal Products for Human Use (CHMP) reaffirmed its concerns about the reliability of the data supporting the drug…
Read More


Discover more from 25finz, L.L.C

Subscribe to get the latest posts sent to your email.

Leave a Reply

Your email address will not be published. Required fields are marked *

Social Media Auto Publish Powered By : XYZScripts.com